GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...

Just before the end of 2025, the idea of taking GLP-1 pills instead of injections moved much closer to reality. On December 22, the U.S. Food and Drug Administration (FDA) approved an oral version of ...

MG continues to make leaps and bounds with the quality and presentation of its products, but the MG S5 shows where that progress might be slowing. The MG S5 EV sits on a slightly larger footprint than ...

On December 22, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration approved its 25 mg oral Wegovy weight-loss pill—the first FDA-approved oral GLP-1 therapy for chronic weight ...

The FDA has approved an oral version of Wegovy, Novo Nordisk's weight-loss drug. The pill is a 25-mg oral formulation of semaglutide, expected to expand market access. Studies show it results in ...

Novo Nordisk’s so-called "oral Wegovy" passed the US Food and Drug Administration (FDA) review on the 22nd, local time. Novo Nordisk announced on the same day that the FDA approved the 25 mg oral ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...

An oral GLP-1 receptor agonist, Rybelsus will be available in 7-mg and 14-mg doses. "As the only FDA-approved GLP-1 therapy in a pill, now recognized for its proven cardiovascular benefits, a new ...

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity ...